疑难病杂志2013，Vol.12Issue(5)：357-359,3.DOI:10.3969/j.issn.1671-6450.2013.05.012
地西他滨联合CAG方案治疗高危骨髓增生异常综合征疗效观察
Clinical study on decitabine combined with CAG regimen in the treatment of high risk myelodysplastic syndromes
摘要
Abstract
Objective To investigate the clinical value about decitabine combined with CAG in the treatment of high risk myelodysplastic syndromes. Methods The 80 cases of patients admitted to hospital were randomly divided into two groups , control group ( n = 40) and treatment group ( n = 40). The control group were only given CAG regimen (Ara-C, Acla, G-CSF) , and the treatment group were also given decitabine . The clinical efficacy , the time of survival, the level of vascular endothelial growth factor (VEGF) , and the adverse reactions in 2 groups were observed and compared after 6 treatment courses. Results The total overall response rate in the treatment group was significantly higher than pretreatmen and the control group (77.5% vs55.0%,P <0.05); the overall survival and disease free survival in the treatment group was signifi -cantly longer than the control group (32. 50 ±21. 64) months vs (24. 07 ± 15. 23) months and(26. 88 ± 17. 02) months vs(20. 11 ±10.45) months respectively , P < 0. 05) ; the levels of VEGF in the treatment group Id, 3d, 7d, 14d after treatment were significantly lower than the control group ( P < 0. 05) ; the main adverse reactions were arrest of bone marrow and lung infec -tion in 2 groups , it was well tolerated. Conclusion The clinical application of decitabine combined with CAG regimen in the treatment of high risk myelodysplastic syndromes are safety and efficacy .关键词
骨髓增生异常综合征,高危/地西他滨/临床疗效Key words
Myelodysplastic syndromes , high risk/ Decitabine / Clinical value引用本文复制引用
于奇宁,常新东,刘先桃,孙莹..地西他滨联合CAG方案治疗高危骨髓增生异常综合征疗效观察[J].疑难病杂志,2013,12(5):357-359,3.
